Evaluation of SeHCAT test in determining ileal involvement and dysfunction in Crohn's disease

LAWRENCE WOROBETZ, MD, ALEX WILKINSON, MD, CHESTER CHMIELOWIEC, MD, LEONARD TAN, MB, PhD

In view of the imperfect methodology that exists for the detection of terminal ileal disease, the authors examined the ability of the SeHCAT test to detect ileal involvement and dysfunction in patients with inflammatory bowel disease. An attempt was also made to correlate the 23-selena-25-homotaurocholate retention (SeHCAT) test with disease activity, extent of ileal disease, presence of diarrhea and response to cholestyramine.

Forty-three patients were studied, including 12 controls – 22 with Crohn's disease limited to the small bowel and none with ulcerative or granulomatous colitis. The mean SeHCAT retention values were 25, 4 and 47%, respectively, all significantly different from each other (P<0.05). This gave a sensitivity of 91%, a specificity of 81% and an accuracy of 86%. No correlation could be established between the SeHCAT retention value and disease activity, extent of ileal disease, presence of diarrhea or response to cholestyramine.

Key Words: Bile salts, Crohn's disease, SeHCAT test

Crohn's disease is a chronic inflammatory disorder potentially involving any level of the gastrointestinal tract but with a predilection to involve the terminal ileum. The methods that presently exist for detecting disease of the terminal ileum are imperfect. The Schilling's test is neither sensitive for limited ileal disease nor specific (1). The C14-conjugated bile acid excretion with fecal collection is more specific and sensitive than the bile acid breath test (2-6); however, it is difficult as a routine clinical test. Barium examination underestimates the presence of terminal ileal disease and is not a test of ileal function (7-9). Endoscopic examination and biopsy of the terminal ileum are technically demanding and, again, are not tests of ileal function.

An available method is the selenium-labelled synthetic conjugated trihydroxy bile acid called 75-SeHCAT (75 se-23-selena-25 homotaurocholic acid) (10,11). The absorption and excretion of SeHCAT is similar to cholic acid being absorbed by the terminal ileum and excreted solely by the biliary system. By virtue of the gamma ray emissions, it can be measured by whole body counting and by uncollimated gamma camera measurements (12). It
has been proposed that measurement of SeHCAT retention is a simple and acceptable test for investigating ileal function, especially in inflammatory bowel disease (13-20). The purpose of this study was to evaluate the ability of the SeHCAT test to determine ileal involvement and dysfunction in patients with inflammatory bowel disease.

An attempt was also made to correlate the SeHCAT retention with the extent of terminal ileal disease, the Crohn's disease activity index (CDAI), the presence of diarrhea and its response to cholestyramine, and appropriate endoscopic and radiological studies. Of these seven, four had clinically active disease.

**Procedures:** The isotope procedure included the oral administration of 0.37 MBq of 75 SeHCAT in capsule form after a 3 h fast. The initial count was measured 3 h after the intake of the isotope with the patient supine and then prone beneath an uncollimated gamma camera at a distance of 42 cm from the table top, centred to the patient's umbilicus. The activity of the 75 SeHCAT was measured using a 20% window around the 266 KeV photon peak. All counts were for 300 s. The geometric mean of the anterior and posterior counts was then calculated. The mean of the two background counts was subtracted from the geometric mean to give the final patient count. The second measurement was performed on day 7 in a similar fashion with no intervening dietary or activity changes. The measurement was corrected for decay and a percentage of the retained activity calculated with values equal to or greater than 19% was considered normal.

In those patients with known Crohn's disease, the CDAI was calculated for the week the test was being performed. All patients with clinical diarrhea (defined as unformed stool more than three times per day) were offered cholestyramine following the SeHCAT study at an initial dose of 4 g/day, increased to 8 g/day after one week if no response. The clinical response was compared with the SeHCAT value, with clinical response being defined as a stool becoming formed with a frequency of less than three times per day. A correlation was also sought between the SeHCAT test and the amount of the terminal ileum resected or involved with Crohn's disease.

Statistical analysis was carried out by using the nonparametric Mann-Whitney test of analysis.

**RESULTS**

The mean ± SE SeHCAT retention for the control group of 12 normal individuals was 25.0±3.2%. In this group, three individuals had abnormally low SeHCAT retention values (14, 11 and 6%), representing apparent false positives. One individual with a false positive result was verified by repeat SeHCAT study (14 and 12%). In all three, the Schilling's test and radiological study of the terminal ileum were normal. All three continue to remain well without diarrhea or other intestinal symptoms after one year follow-up.

In patients with Crohn's disease, the overall mean SeHCAT retention value of those with terminal ileal disease and/or resection was 5.0±2.0%, significantly different from the control group (P<0.01). This group included two false negatives with SeHCAT values of 20 and 29%; one patient had 11 cm of terminal ileum resected with 10 cm of recurrent proximal disease and the other had 25 cm of terminal ileal involvement. Neither had evidence of colonic involvement.

The mean SeHCAT value in patients with ulcerative or granulomatous colitis was 47.5±6.7% which was significantly higher than the mean for the terminal ileal disease group (P<0.01). It was also significantly higher than the mean for the control group (P<0.05) (Figure 1). In this group of colitis patients, there was one false positive, a patient labelled as left-sided ulcerative colitis whose SeHCAT value was 15% and, after a one-year follow-up, continues to demonstrate a radiologically normal terminal ileum and Schilling's test. The two highest values in this group (79 and 64%) were individuals with active panulcerative colitis.
Thus, in the group of 43 patients, there were 20 true positives, four false positives, two false negatives and 17 true negatives. This gives a sensitivity for the SeHCAT test of 91%, a specificity of 81% and an accuracy of 86%.

Assuming the distal ileum to be 100 cm, a relationship was sought between the percentage retention of SeHCAT and the residual length of the terminal 100 cm of ileum. The coefficient of correlation was 0.457 (P=0.163) for patients with ileocaecal valve (open circles) and -0.134 (P=0.742) for those with resected ileocaecal valve (filled circles).

In patients with terminal ileal disease and/or resection, 20 of 22 patients also had a low SeHCAT retention value; of this group, 13 (65%) had diarrhea while seven (35%) did not. In the group with diarrhea, only seven (54%) responded to the cholestyramine therapy. Thus, a low SeHCAT retention value (less than 19%) in patients with terminal ileal Crohn’s disease did not reliably predict the presence of diarrhea or the clinical response of those with diarrhea to cholestyramine.

There was no correlation established between the CDAI and the SeHCAT retention values (correlation coefficient =0.25). The mean of those with active Crohn’s disease (CDAI more than 150) was 4.0±1.2% while the mean of those with inactive disease (CDAI less than 150) was 3.0±1.8% (Figure 3).

The mean length of terminal ileal involvement/resection in those with diarrhea was 45.8±4.1 cm (range 25 to 75) which was significantly different from those without diarrhea, the mean being 23.9±10.8 cm (range 2 to 84) (P<0.05). In those who clinically responded to cholestyramine, the mean length of involvement/resection was 35.3±5.4 cm (range 25 to 50) and in those who did not respond it was 46.4±6.1 cm (range 25 to 75). The difference was insignificant [P=0.29].

**DISCUSSION**

The SeHCAT test is a test of bile salt absorption and has been proposed as a test of ileal function. In this study, it appears that in patients with Crohn’s disease, a low SeHCAT retention value strongly correlates with ileal involvement. However, the sensitivity of 91% and specificity of 81% for the SeHCAT test is this study are not as high as previous studies quoting as high as 94% sensitivity and 100% specificity. The reasons for this are unclear. In our study, a value of greater than 19% for SeHCAT retention at day 7 was con-
sidered normal. Values between 12 and 19% have previously been defined as equivocal. If, for this study, the values of 12% or lower were defined as abnormal, this would have the effect of reducing the sensitivity to 82%, increasing the specificity to 90% but not changing the accuracy of 85%. Recent observations claim improved sensitivity with three-day retention readings or analysis of activity versus time monoeponential curves calculated by the least squares method. Recently shown is that data uncorrected for colonic retention overestimate SeHCAT absorption to a variable degree with a resulting reduction in accuracy of the test. This would likely be of importance in those without diarrhea.

Indeed, the true sensitivity and specificity of the SeHCAT test is difficult to determine as we do not have a gold standard for diagnosing ileal dysfunction against which to compare. However, the sensitivity and specificity values in this study of patients with morphological evidence of Crohn’s disease limited to the ileum are equal to or better than the reported values for other ileal function tests, including the Schilling’s test, bile acid breath test and the C14-conjugated bile acid stool collection. In view of this and of the simplicity of the test, the SeHCAT test could be considered an appropriate investigation for diagnosing ileal involvement in Crohn’s disease, especially in distinguishing those with isolated large bowel involvement from those with isolated ileal involvement. The highest retention values were achieved by patients with active pancolitis. Although up to 30% of the daily bile salt load can be absorbed by the healthy colon, the handling of bile salts by the inflamed colon is unknown. In this study, given that the SeHCAT retention values are significantly elevated in active colitis versus control values, this implies an enhanced absorption of bile salts by the inflamed colon which could potentially lead to a false negative SeHCAT retention value in patients with both ileal and extensive colonic involvement.

As would be expected, the SeHCAT values do not correlate with disease activity as measured by the CDI, but correlates with the presence of ileal involvement, whether active, inactive or surgically removed. No correlation could be established between the SeHCAT value and the amount of terminal ileal remaining, which may represent a type II error as prior studies have suggested such a relationship. As the majority of SeHCAT retention values for terminal ileal disease/resection are very low, it is possible that earlier readings on day 3 or calculation of the area under the retention curve may be more accurate in quantitating the rate of bile salt loss and, thus, more accurately correlate with the extent of ileal disease/resection.

In agreement with prior studies is the observation that patients with an intact ileocecal valve have a greater retention of bile salts and less diarrhea. This may be explained in part by the fact that those with intact ileocecal valves usually have less ileum diseased or resected. Alternatively, the ileocecal valve may function sufficiently to slow fecal flow in the ileal area to allow more efficient absorption of bile salts. This would support the belief that the ileocecal valve should be preserved during surgery whenever possible.

Low SeHCAT retention values do not predict the presence of diarrhea, as 35% of those with terminal ileal disease and low SeHCAT retention values had normal bowel habits with no clinical evidence of bile salt catharsis. Furthermore, a low SeHCAT retention value in those with diarrhea and with Crohn’s disease limited to the terminal ileum is not clinically useful in predicting the clinical response to cholestyramine therapy. Clearly the SeHCAT test is able to demonstrate bile salt loss but the test is unable to establish a causal relationship between bile salt malabsorption and diarrhea. This is understandable given the multiple mechanisms in Crohn’s disease besides bile salt catharsis that may contribute to diarrhea. Thus it appears simpler to give an empiric trial of cholestyramine than to investigate the symptomatic patient with a SeHCAT test to determine whether bile salt catharsis is of importance clinically.

REFERENCES
1. Fromm H, Thomas PJ, Hofmann AF. Sensitivity and specificity in tests of distal ileal function. Prospective comparison of bile acids and vitamin B12 absorption in ileal resection patients. Gastroenterology 1973;64:1077-90.
2. Lenz K. An evaluation of the breath test in Crohn’s disease. Scand J Gastroenterol 1975;10:665-71.
3. Thaysen EH. Diagnostic value of the 14C-choly glycine breath test. Clin Gastroenterol 1977;6:227-30.
4. Heaton KW. Bile salt tests in clinical practice. Br Med J 1979;i:644-6.
5. Lawlerburg BH, Mewcomer AD, Hofmann AF. Clinical value of the bile acid breath test. Evaluation of the Mayo Clinic Experience. Mayo Clin Proc 1978;53:227-33.
6. Scarpaello JHB, Sladen GE. Appraisal of the 14C-glycolcholate acid breath test with special reference to the measurement of faecal 14C excretion. Gut 1977;18:742-8.
7. Elliott PR, Williams CB, Leonard-Jones JE. Colonicoscopy diagnosis of minimal changes in patients with normal sigmoidoscopy and normal air contrast barium enema. Lancet 1982;i:650-1.
8. Popov OS, Kostic KM, Milovic VB, et al. Primary bile acid malabsorption. Histologic and immunologic study in three patients. Gastroenterology 1987;92:1851-8.
9. Gabrielson N, Granquist S, Sundelin P, et al. Extent of inflammatory lesions in ulcerative colitis assessed by radiology, colonoscopy and endoscopic biopsies. Gastrointest Radiol 1979;4:395-400.
10. Boyd GS, Merrick MV, Monks R, et al. 75Se-labelled bile acid analogues. New radiopharmaceuticals for investigating the enterohepatic circulation. J Nucl Med 1981;22:720-5.
11. Merrick MV, Eastwood MA, Anderson JR, et al. Enterohepatic circulation in man of a gamma-emitting bile acid conjugate, 23-seleno-25-homotaurocholic acid (SeHCAT). J Nucl Med 1982;23:126-30.
12. Hames TK, Condon BR, Fleming JS, et al. A comparison between the use of a shadow shield whole body counter and an uncollimated gamma camera in the assessment of the seven-day retention of SeHCAT. Br J Radiol 1984;57:581-4.
13. Fagan EA, Chadwick VS, McLean B. SeHCAT absorption: A simple test of
ileal dysfunction. Digestion 1983;26:159-65.

14. Sciarretta G, Vicini G, Fagloli G, et al. Use of 23-selena-25-homocholyltaurine to detect bile acid absorption in patients with ileal dysfunction or diarrhoea. Gastroenterology 1986;91:1-9.

15. Nyhlin H, Merrick MV, Eastwood MA, et al. Evaluation of ileal function using 23-selena-25-homotaurocholate, a gamma-labelled conjugated bile acid. Gastroenterology 1983;84:63-8.

16. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. Gastroenterology 1976;70:439-44.

17. Ferraris R, Jasran R, Bridges C, et al. Use of a gamma-labelled bile acid (75SeHCAT) as a test of ileal function. Gastroenterology 1986;90:1129-36.

18. Schiller LR, Hogan RB, Moranski SG, et al. Studies of the prevalence and significance of radio-labelled bile acid malabsorption in a group of patients with idiopathic chronic diarrhoea. Gastroenterology 1987;92:151-60.

19. Mokhjian HS, Phillips SF, Hofmann AF. Colonic absorption of unconjugated bile acids. Perfusion studies in man. Dig Dis Sci 1979;24:545-50.

20. D'Arienzo A, Maurelli L, DiSiervi P, et al. The role of 75-selenium-homotaurocholate test (SeHCAT) in Crohn's disease. Gastroenterology Int 1988;1:539.
